Midwest Melanoma Partnership and Accelovance, Inc. Enhance Melanoma Research Offering Through Strategic Alliance

Sep 15, 2015, 02:00 ET from Accelovance

ROCKVILLE, Md. and ROCHESTER, Minn., Sept. 15, 2015 /PRNewswire-USNewswire/ -- Accelovance, Inc. (Accelovance), a global contract research organization (CRO) focusing in oncology, vaccines, and general medicine and the Midwest Melanoma Partnership (MMP), a non-profit organization dedicated to improving therapies for patients diagnosed with malignant melanoma, have entered into a strategic alliance to enhance the research and advancement of treatment options for patients suffering from melanoma.

The strategic alliance provides pharmaceutical and biotechnology companies with enhanced access to melanoma key opinion leaders, expedited contracting and protocol review within MMP's 19 academic and community-based research center members, and Accelovance's oncology-experienced clinical and project staff within the United States and Europe.

Svetomir Markovic, MD, PhD, Chairman of the Midwest Melanoma Partnership, stated, "MMP is excited to partner with Accelovance to provide this comprehensive offering to drug development companies. Facilitating expanded access to medical and scientific feedback and expediting clinical trial initiation ultimately provides an enhanced opportunity to advance treatment options for our patients suffering from melanoma."

Jamie Oliver, PharmD, Accelovance's Chief Science Officer added, "Creating this strategic alliance with MMP provides a valuable integrated service offering to pharmaceutical and biotech companies undertaking development work in melanoma. This collaboration aligns key opinion leader and scientific leadership with clinical operations and trial execution-experienced staff to enhance and expedite clinical trial research and drug approval."

About Midwest Melanoma Partnership (MMP)
MMP is a multi-institutional collaboration of physicians, scientists, and patient advocates dedicated to the development of improved therapies for patients with malignant melanoma. Composed of 19 member organizations well known within the academic and community research field (http://www.midwestmelanoma.org/?page_id=39), member organizations work within their institution and across MMP membership institutions to participate in clinical trials to advance treatment options for patients diagnosed with melanoma. For more information, visit the organization's website at www.midwestmelanoma.org.

About Accelovance
Accelovance, Inc., headquartered in Rockville, MD, is an industry award-winning global Contract Research Organization (CRO) focused primarily in oncology, vaccines, and general medicine. As a clinical services provider to the pharmaceutical and biotechnology industries, Accelovance offers comprehensive clinical development services including the management and implementation of Phase I-IV clinical trials and Clinical Engagement Solutions utilized for recruitment, post-marketing surveillance, and long-term survival follow-up. For more information, visit the company's website at www.accelovance.com.  

Accelovance Press Contact
Michael Keens, VP Business Development
240.238.4941
mkeens@accelovance.com
Twitter: @Accelovance

MMP Press Contact
Lisa Kottschade, Chief Operating Officer
507.538.7888
rstmmpadmin@mayo.edu
Twitter: @mmpmelanoma

Logo - http://photos.prnewswire.com/prnh/20140219/DC68221LOGO

 

SOURCE Accelovance



RELATED LINKS

http://www.accelovance.com